Lepu medical has obtained exenatide, the first generic drug of Chengdu sannuo 3 + 6 diabetes

According to the company's insiders, this cooperation is mainly based on technical cooperation After the approval, Chengdu shengnuo is still responsible for the production Lepu medical is responsible for the pricing and sales after the production and pays the production costs of Chengdu shengnuo However, it is too early to establish a sales team This cooperation marks that Lepu medical has officially entered the field of diabetes drugs, which is in line with the company's development strategy of establishing a platform for diabetes drugs and cardiovascular drugs Exenatide is a synthetic intestinal hypoglycemic hormone analogue, which is often used as an adjuvant in the treatment of type 2 diabetic patients with insufficient blood glucose control after taking metformin or sulfonylurea alone or in combination with metformin and sulfonylurea Since its launch in the United States in April 2005, exenatide has been listed as the top four potential drugs by international diabetes experts China is the second most high incidence country of diabetes, with a huge market of antidiabetic drugs According to the website of CFDA, exenatide injection was jointly developed by Bristol Myers Squibb and AstraZeneca Apart from the original research drug, there are no other domestic enterprises producing and selling the injection Only one Baike biological company under Changchun hi tech (000661 SZ) which applied for production at the same time with Chengdu shengnuo In addition, nearly 10 enterprises are applying for the clinical approval documents of the drug, including Qilu pharmaceutical, LVYE pharmaceutical, Shuangcheng Pharmaceutical (002693 SZ), tag Pharmaceutical (300347 SZ), etc.